On 9/6/22 the FDA approved Stanford’s SAINT Neuromodulation, an accelerated version of TMS that has raised hopes with unusually high remission rates.

Antidepressants in mania and stimulants in psychotic disorders get called out in our first psychopharm commandment. 

Silexan, an extract from Lavender with pharmaceutical properties, is one of only two treatments with a large effect size in generalized anxiety disorder. We rank all the treatments by strength and look to see if any of them can work when the SSRIs do not.

Richard Brown discusses symptoms that often get in the way of full recovery in ADHD, including dyslexia, and problems with working memory, processing speed, and executive function. 

Topiramate can cause psychosis, or treat psychosis; worsen cognition, or improve it; cause depression or… You get the point. A look at the paradoxical world of psychopharmacology.

Carl Salzman removes the stigma from the much maligned benzo, reminding us of when they are essential to treatment and when they cause harm. Dr. Salzman is the past chairman of the American Psychiatric Association’s Benzodiazepine Task Force.

Psychotic depression. Conrad Swartz shows us how to recognize this underdiagnosed illness, and why antipsychotics and antidepressants may not be the optimal treatment. 

12 clinically relevant findings from the past 3 years on quetiapine (Seroquel), including new side effects, dosing strategies, withdrawal phenomena, and new uses in bipolar with OCD.

Tricyclics are much better tolerated than their reputation suggests, and countdown 6 reasons to use them, from melancholic depression to irritable bowel syndrome.